BioLineRx (BLRX) Other Non-Current Assets (2012 - 2019)
BioLineRx (BLRX) posted Other Non-Current Assets of $56000.0 for Q4 2019, down 5.08% on a QoQ basis from $59000.0 in Q3 2019, and up 1020.0% year-over-year from $5000.0 in Q4 2018.
BioLineRx (BLRX) has 8 years of Other Non-Current Assets data on file, last reported at $56000.0 in Q4 2019.
- In Q4 2019, Other Non-Current Assets rose 1020.0% year-over-year to $56000.0; the TTM figure through Dec 2019 stood at $56000.0 (up 1020.0% YoY), while the FY2019 annual figure was $56000.0, up 1020.0% from the prior year.
- Other Non-Current Assets retreated to $56000.0 in Q4 2019, from $59000.0 in the prior quarter.
- Across five years, Other Non-Current Assets topped out at $1.0 million in Q4 2016 and bottomed at -$9000.0 in Q4 2015.
- A 5-year average of $77800.0 and a median of $53500.0 in 2016 frame the typical range for Other Non-Current Assets.
- Annual changes were most pronounced in 2015 — Other Non-Current Assets sank 170.0% — and 2016, when it soared 11211.11%.
- Year by year, Other Non-Current Assets stood at -$9000.0 in 2015, then soared by 11211.11% to $1.0 million in 2016, then plunged by 100.9% to -$9000.0 in 2017, then surged by 155.56% to $5000.0 in 2018, then jumped by 1020.0% to $56000.0 in 2019.
- The last three Other Non-Current Assets figures came in at $56000.0 (Q4 2019), $59000.0 (Q3 2019), and $60000.0 (Q2 2019), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 12.40 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | 60,000.00 |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 1.26 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 2.13 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 63.55 Mn |
| 10 | BioLineRx | 9.32 Bn | 9.30 Bn | 154,000.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2019 | 56,000.00 |
| Sep 30, 2019 | 59,000.00 |
| Jun 30, 2019 | -4,000.00 |
| Mar 31, 2019 | 1,000.00 |
| Dec 31, 2018 | 5,000.00 |
| Sep 30, 2018 | 66,000.00 |
| Jun 30, 2018 | 63,000.00 |
| Mar 31, 2018 | 60,000.00 |
| Dec 31, 2017 | -9,000.00 |
| Sep 30, 2017 | -8,000.00 |
| Jun 30, 2017 | -1,000.00 |
| Mar 31, 2017 | -3,000.00 |
| Dec 31, 2016 | 1.00 Mn |
| Sep 30, 2016 | 4,000.00 |
| Jun 30, 2016 | 4,000.00 |
| Mar 31, 2016 | 2,000.00 |
| Dec 31, 2015 | -9,000.00 |
| Sep 30, 2015 | -7,000.00 |
| Jun 30, 2015 | 57,000.00 |
| Mar 31, 2015 | -1,000.00 |
| Dec 31, 2014 | -6,000.00 |
| Sep 30, 2014 | 10,000.00 |
| Jun 30, 2014 | 2,000.00 |
| Mar 31, 2014 | 55,000.00 |
| Dec 31, 2013 | 10,000.00 |
| Sep 30, 2013 | 41,000.00 |
| Jun 30, 2013 | 47,000.00 |
| Mar 31, 2013 | 53,000.00 |
| Dec 31, 2012 | 54,000.00 |